only risk that our protocol would produce for the patient is the unlikely 
possibility of a malignancy resulting from insertional mutagenesis. Considering 
the fact that all of the patients we are treating have advanced cancers that have 
failed all available effective therapy and that we are attempting to develop new 
approaches to the treatment of this devastating disease, we maintain that the 
risks in our gene transfer protocol are minimal when compared with the potential 
benefits to be gained from the knowledge that would accrue. 
Respectfully submitted, 
W. French Anderson, M.D. 
R. Michael Blaese, M.D. 
Steven A. Rosenberg, M.D., Ph.D. 
[ 214 ] 
Recombinant DNA Research, Volume 13 
